Tag: closing price

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Intuit (INTU) To Contact Him Directly To Discuss Their Options

MONROE TOWNSHIP, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 25,000,000 shares of the Company’s common stock together with common warrants to purchase up to 25,000,000 shares of common stock in a registered direct offering at a combined purchase price of $0.40 per share of common stock and accompanying common warrant. The offering was priced at a premium to yesterday’s closing price. The common warrants will be exercisable on the six month anniversary of the date of issuance at an exercise price of $0.40 per share and will expire 6 years from the initial date of exercise.

Liven AS (Liven) disposed of a total of 1,900 Liven shares to its employees on 2 June 2026 under the 2024–2027 share option programme (Programme) at a price of EUR 3.71 per share. The ongoing Programme was approved by Liven’s annual general meeting on 19 April 2024, and the transaction price was agreed based on the latest available market price, the closing price on 1 June 2026.

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Reddit (RDDT) To Contact Him Directly To Discuss Their Options

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.

Highlights and subsequent events